Clinical Trials Update: Dec. 19, 2006
Multiple Sclerosis Liver Cancer Alzheimer's Disease
(HealthDay News) -- Here are the latest clinical trials, courtesy of Thomson CenterWatch:
This study will evaluate an investigational use of a medication called natalizumab to treat multiple sclerosis. Volunteers 18-55 who have not had prior treatment with natalizumab, any murine protein, or any other therapeutic monoclonal antibody may qualify.
The research site is in Tacoma, Wash.
This clinical study will evaluate whether a treatment currently known as BMS-582664 can shrink or slow the growth of advanced liver cancer. Candidates with a diagnosis of hepatocellular carcinoma (HCC) greater than 2 cm who have not had a heart attack within 12 months or uncontrolled chest pain within six months may be eligible.
The research sites are worldwide.
This clinical study will determine the effects of an investigational drug on daily function and memory in people with Alzheimer's disease. Patients 50-90 may be included who have been diagnosed with mild-to-moderate Alzheimer's, are in generally good health, and who can be accompanied by a regular caregiver to 10 study visits over a 54-week period. Participants will receive all study-related medical care, physical exams, lab tests, and the investigational drug at no cost.
The research site is in Sherman Oaks, Calif.
Copyright 2006 Thomson CenterWatch. All rights reserved.